Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — U.S. June 2021–February 2022

Plumb, Ian D.; Feldstein, Leora R.; Barkley, Eric; Posner, Alexander B.; Bregman, Howard S.; Hagen, Melissa Briggs; Gerhart, Jacqueline L.

doi:10.15585/MMWRmm7115e2

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — U.S. June 2021–February 2022

4 15 2022
By Plumb, Ian D. ; Feldstein, Leora R. ; Barkley, Eric ; ...
http://dx.doi.org/10.15585/MMWRmm7115e2
Source: MMWR Morb Mortal Wkly Rep. 71(15):549-555

[PDF-145.02 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

MMWR Morb Mortal Wkly Rep
Personal Author:

Plumb, Ian D. ; Feldstein, Leora R. ; Barkley, Eric ; Posner, Alexander B. ; Bregman, Howard S. ; ... More +

Plumb, Ian D. ; Feldstein, Leora R. ; Barkley, Eric ; Posner, Alexander B. ; Bregman, Howard S. ; Hagen, Melissa Briggs ; Gerhart, Jacqueline L. Less -
Description:

Previous infection with SARS-CoV-2, the Virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron Variants compared with that against other SARS-CoV-2 Variantss (1-3). A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or Diagnosis of COVID-19.| The Analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result). After previous SARS-CoV-2 infection, estimated vaccine effectiveness (VE) against COVID-19-associated hospitalization was 47.5% (95% CI = 38.8%-54.9%) after 2 vaccine doses and 57.8% (95% CI = 32.1%-73.8%) after a booster dose during the Delta-predominant period (June 20-December 18, 2021), and 34.6% (95% CI = 25.5%-42.5%) after 2 doses and 67.6% (95% CI = 61.4%-72.8%) after a booster dose during the Omicron-predominant period (December 19, 2021-February 24, 2022). Vaccination provides protection against COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection, with the highest level of protection conferred by a booster dose. All eligible persons, including those with previous SARS-CoV-2 infection, should stay up to date with vaccination to prevent COVID-19-associated hospitalization.
Subjects:

[+]

Adolescent Adult COVID-19 Hospitalization Humans RNA, Messenger SARS-CoV-2 Vaccination
Source:

MMWR Morb Mortal Wkly Rep. 71(15):549-555
Pubmed ID:

35421077
Pubmed Central ID:

PMC9020856
Document Type:

Journal Article
Place as Subject:

U.S.
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha256:7beea985bb2a45b4dbfe5c5bd6f382ed1b4cc81d346c860ac9eb5b46f2b24ad2
Download URL:

https://stacks.cdc.gov/view/cdc/117047/cdc_117047_DS1.pdf
File Type:

mm7115e2.nxml

xml

More +